Company intelligence / Profile preview

IBEX Pharmaceuticals

Montreal, Quebec, Canadaibexpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

IBEX Pharmaceuticals was a leading manufacturer of high-purity recombinant enzymes for biomedical research and clinical diagnostics. Its proprietary glycosaminoglycan-degrading enzymes—especially heparinases—are used globally in FDA and EU-approved point-of-care devices for measuring hemostasis. The company was acquired by BBI Solutions in April 2024.

Therapeutic areas: Hematology
Modalities: ProteinRecombinant proteinEnzyme
Industry: Chemicals & Materials

Drug pipeline

2 assets

Heparinase I

Commercial

Indications: Hemostasis testing

1 more asset in the full pipeline.

Request access →

Partnerships

Part of BBI Solutions' global networkSupplied major diagnostic device manufacturers with critical raw materials

Beyond the preview

Go deeper on IBEX Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBEX Pharmaceuticals.

Explore the full profile